3rd Circ. Revives Fresenius Generic Drug Suit
The Third Circuit on Monday revived Fresenius Kabi USA LLC's antitrust claims that Par Pharmaceuticals delayed Fresenius from marketing a generic blood pressure medication due to Par's exclusive ingredient supply arrangements,...To view the full article, register now.
Already a subscriber? Click here to view full article